Discussing Seladelpar as a Potential Therapeutic for PBC

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how seladelpar showed remarkable efficacy in the RESPONSE trial, demonstrating significant improvements in alkaline phosphatase levels and other biochemical markers compared with placebo.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

EP: 4.Exploring Second-Line Treatments for PBC

EP: 5.Examining Elafibranor as a Treatment Option for PBC

Now Viewing

EP: 6.Discussing Seladelpar as a Potential Therapeutic for PBC

EP: 7.Long-Term Considerations for PBC Treatment Options

EP: 8.Safety Considerations When Initiating Treatment for PBC

EP: 9.Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies

EP: 10.Additional Safety Considerations With PBC Treatments

EP: 11.Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis

EP: 12.Long-Term Safety of Second-Line Therapies for PBC

EP: 13.Best Practices in Switching PBC Therapies

EP: 14.Monitoring Patients Transitioning From Obeticholic Acid

EP: 15.Additional Considerations With PBC Therapies

Video content above is prompted by the following:

Seladelpar has been studied extensively, with the RESPONSE trial serving as one of its landmark studies. What are the key efficacy findings from this trial?